Keros Therapeutics, Inc.

NasdaqGM:KROS 株式レポート

時価総額：US$210.0m

Keros Therapeutics マネジメント

マネジメント 基準チェック /34

Keros Therapeuticsの CEO はJas Seehraで、 Dec2015年に任命され、 の在任期間は 10.58年です。 の年間総報酬は$ 2.54Mで、 27.6%給与と72.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.88%を直接所有しており、その価値は$ 3.96M 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と4.4年です。

主要情報

Jas Seehra

最高経営責任者

US$2.5m

報酬総額

CEO給与比率27.56%
CEO在任期間10.6yrs
CEOの所有権1.9%
経営陣の平均在職期間6.3yrs
取締役会の平均在任期間4.4yrs

経営陣の近況

Recent updates

分析記事 • Nov 18

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Aug 21

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Summary Keros Therapeutics, Inc. faces uncertainty after discontinuing its lead asset, with current value driven mainly by a strong cash position and pipeline potential. KER-065 received FDA Orphan Drug designation for Duchenne Muscular Dystrophy, but efficacy and approval remain years away and unproven. Elritercept, now partnered with Takeda, offers milestone and royalty potential, but faces tough competition and uncertain commercial prospects. Given limited near-term catalysts and high risk, I maintain a Hold rating—Keros is interesting, but KROS stock lacks enough data for a bullish stance. Read the full article on Seeking Alpha
分析記事 • May 29

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Key Insights Keros Therapeutics to hold its Annual General Meeting on 4th of June Salary of US$699.0k is part of CEO...
分析記事 • May 14

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We did...
分析記事 • May 09

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shares have had a really impressive month, gaining 44% after a shaky period...
Seeking Alpha • Mar 13

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Summary Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Despite a strong cash position and a Takeda partnership elsewhere, the future of Keros' lead candidate, Cibotercept, appears bleak. The company has a cash runway of 13 quarters, but high short interest and low trading volume pose additional risks. Given the current situation, I recommend avoiding KROS, although risk-loving investors might find its low price and cash reserves appealing. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Summary Keros Therapeutics, Inc.'s stock plummeted over 75% due to halting high-dose arms in its Phase 2 TROPOS trial for PAH, citing safety concerns. Despite the setback, Keros' partnership with Takeda Pharmaceutical Company for elritercept and its potential $900m annual revenue offers a safety net. The market reaction may be too harsh; past biotech clinical study setbacks have often been resolved, presenting a contrarian investment opportunity. Investors should wait for more data on cibotercept's safety issues before making definitive judgments. Read the full article on Seeking Alpha
分析記事 • Nov 20

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Aug 07

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jun 10

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with the FDA and agreed on a design for a phase 3 study using KER-050 for the treatment of low-risk MDS. The global myelodysplastic syndrome market is projected to reach $6.10 billion by 2029. Keros Therapeutics is also developing the use of KER-050 for the treatment of patients with myelofibrosis and data from the phase 2 study for this program is expected in Q4 2024. Read the full article on Seeking Alpha
分析記事 • Apr 23

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Key Insights The projected fair value for Keros Therapeutics is US$94.52 based on 2 Stage Free Cash Flow to Equity...
分析記事 • Sep 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Jun 10

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Sep 08

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 04

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Keros Therapeutics press release (NASDAQ:KROS): Q2 GAAP EPS of -$1.13 misses by $0.07. Cash and cash equivalents OF $215.62M
分析記事 • Apr 29

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jan 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO報酬分析

Keros Therapeutics の収益と比較して、Jas Seehra の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$85m

Dec 31 2025US$3mUS$700k

US$87m

Sep 30 2025n/an/a

US$64m

Jun 30 2025n/an/a

US$19m

Mar 31 2025n/an/a

US$4m

Dec 31 2024US$6mUS$699k

-US$187m

Sep 30 2024n/an/a

-US$182m

Jun 30 2024n/an/a

-US$168m

Mar 31 2024n/an/a

-US$160m

Dec 31 2023US$9mUS$649k

-US$153m

Sep 30 2023n/an/a

-US$142m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$116m

Dec 31 2022US$6mUS$611k

-US$105m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$7mUS$557k

-US$59m

Sep 30 2021n/an/a

-US$61m

Jun 30 2021n/an/a

-US$53m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$10mUS$521k

-US$45m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$695kUS$485k

-US$14m

報酬と市場: Jasの 総報酬 ($USD 2.54M ) は、 US市場 ($USD 1.66M ) の同規模の企業の平均を上回っています。

報酬と収益: Jasの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Jas Seehra (70 yo)

10.6yrs
在職期間
US$2,540,204
報酬

Dr. Jasbir S. Seehra, also known as Jas, Ph D., is President of Keros Therapeutics, Inc. from August 18, 2025 and has been its Chief Executive Officer and Director since December 2015 and was its Chair of...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jasbir Seehra
President10.6yrsUS$2.54m1.88%
$ 4.0m
Keith Regnante
Chief Financial Officer6.4yrsUS$1.11m0.049%
$ 103.8k
Esther Cho
Chief Legal Officer & Secretary6.3yrsUS$1.10m0.20%
$ 421.8k
Justin Frantz
Head of Investor Relationsno dataデータなしデータなし
Lorena Lerner
Chief Scientific Officerless than a yearデータなし0.16%
$ 330.3k
6.3yrs
平均在職期間
55yo
平均年齢

経験豊富な経営陣: KROSの経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。

取締役

名称ポジション在職期間報酬所有権
Jasbir Seehra
President10.6yrsUS$2.54m1.88%
$ 4.0m
Jean-Jacques Bienaime
Independent Chair of the Board2.1yrsUS$259.44k0.058%
$ 121.5k
Julius Knowles
Independent Director10.3yrsUS$239.04k0.019%
$ 40.5k
Mary Gray
Independent Director5.6yrsUS$247.54k0.30%
$ 619.9k
Alpna Seth
Independent Director3.2yrsUS$238.54k0.18%
$ 381.5k
Anne Prener
Directorno dataデータなしデータなし
Nima Farzan
Independent Director6.3yrsUS$239.04k0.24%
$ 506.2k
Charles Newton
Independent Directorless than a yearデータなし0.064%
$ 134.4k
4.4yrs
平均在職期間
66yo
平均年齢

経験豊富なボード: KROSの 取締役会 は 経験豊富 であると考えられます ( 4.4年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/21 17:45
終値2026/07/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Keros Therapeutics, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16

アナリスト機関
Jason ZemanskyBofA Global Research
Corinne JohnsonGoldman Sachs
Andrew FeinH.C. Wainwright & Co.